Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls.
The purpose of this article is to review the role of intensity-modulated radiotherapy (IMRT) in the standard management of patients with head and neck cancer through a critical review of the pertinent literature. IMRT may result in a dose distribution that is more conformal than that achieved with three-dimensional conformal radiotherapy (3D CRT), allowing dose reduction to normal structures and thus decreasing toxicity and possibly enhancing locoregional control through dose escalation. Disadvantages associated with IMRT include increased risk of a marginal miss, decreased dose homogeneity, increased total body dose, and increased labor and expense. Outcomes data after IMRT are limited, and follow-up is relatively short. Locoregional control rates appear to be comparable to those achieved with 3D CRT and, depending on the location and extent of the tumor, late toxicity may be lower. Despite limited data on clinical outcomes, IMRT has been widely adopted as a standard technique in routine practice and clinical trials. The use of IMRT involves a learning curve for the practitioner and will continue to evolve, requiring continuing education and monitoring of outcomes from routine practice. Additional standards pertaining to a variety of issues, including target definitions and dose specification, need to be developed. Phase III trials will better define the role of IMRT in coming years.
Mendenhall
William M
WM
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA. mendewil@shands.ufl.edu
Amdur
Robert J
RJ
Palta
Jatinder R
JR
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000639:trends; D019583:Dose Fractionation, Radiation; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D017410:Practice Guidelines as Topic; D011832:Radiation Injuries / Q000517:prevention & control; D018787:Radiation Oncology / Q000193:education; D020266:Radiotherapy, Conformal; D050397:Radiotherapy, Intensity-Modulated; D016032:Randomized Controlled Trials as Topic; D009626:Terminology as Topic; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D002945:Cisplatin